急性心肌梗死患者血清中 BIN1 水平与 Killip 分级之间的关系

doi:10.12122/j.issn.1673-4254.2024.12.15

南方医科大学学报 ›› 2024, Vol. 44 ›› Issue (12): 2388-2395.doi: 10.12122/j.issn.1673-4254.2024.12.15

• • 上一篇

急性心肌梗死患者血清中 BIN1 水平与 Killip 分级之间的关系

王燕妮¹(), 黄霞¹, 陈福恒², 高圆圆³, 崔向荣⁴, 严琴⁵, 井宣¹()

^1.山西医科大学第五临床医学院检验科，山西太原 030012
^2.山西省人民医院检验科，山西太原 030012
^3.实验动物中心统计学部门，山西太原 030012
^4.山西省妇幼保健院生殖医学科，山西太原 030013
^5.山西医科大学第二临床医学院，山西太原 030002

收稿日期:2024-03-13 出版日期:2024-12-20 发布日期:2024-12-26
通讯作者: 井宣 E-mail:wyn_Emma@163.com;jx05070103@163.com
作者简介:王燕妮，在读硕士研究生，E-mail: wyn_Emma@163.com
基金资助:
国家自然科学基金(82000302);山西省留学人员科技活动择优资助项目(20200033);山西省应用基础研究计划项目(201901D211519)

Association between serum BIN1 level and Killip class in patients with acute myocardial infraction

Yanni WANG¹(), Xia HUANG¹, Fuheng CHEN², Yuanyuan GAO³, Xiangrong CUI⁴, Qin YAN⁵, Xuan JING¹()

^1.Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China
^2.Clinical Laboratory, Shanxi Provincial People's Hospital, Fifth Hospital of Shanxi Medical University, Taiyuan 030012, China
^3.Statistics for Laboratory Animal Centre, Shanxi Provincial People's Hospital, Taiyuan 030012, China
^4.Reproductive Medicine Center, Women and Children's Health Center of Shanxi Province, Taiyuan 030013, China
^5.Second Clinical College of Shanxi Medical University, Taiyuan 030002, China

Received:2024-03-13 Online:2024-12-20 Published:2024-12-26
Contact: Xuan JING E-mail:wyn_Emma@163.com;jx05070103@163.com
Supported by:
National Natural Science Foundation of China(82000302)

摘要/Abstract

摘要：

目的探讨急性心肌梗死（AMI）与血清桥接整合因子（BIN1）水平之间的相关性和Killip分级之间的关系。方法实验组包括94例AMI患者，对照组包括30例未患AMI的健康体检者。检测在对照组和AMI组之间、不同Killip分类之间以及3个不同TIMI评分组之间的血清BIN1表达水平。并评估AMI患者的中性粒细胞与淋巴细胞比值（NLR）以及与BIN1的联合诊断价值。结果 AMI组血清BIN1水平低于对照组（P=0.032）。Killip Ⅰ组的血清BIN1水平低于对照组（P=0.008）。血清BIN1水平是AMI组的独立预测因子，其预测值为0.630（95% CI：0.513-0.748），临界值为0.341 ng/mL，特异性为 50%，灵敏度为 78.5%；血清BIN1水平也是Killip Ⅰ组的独立预测因子，其预测值为0.672（95% CI：0.548-0.797），最佳临界值为0.287 ng/mL，特异性为74.1%，灵敏度为60%。NLR和血清BIN1水平联合预测AMI为0.811（95% CI：0.727-0.895），最佳临界值为0.548ng/mL，特异性为92.6%，灵敏度为62.2%。血清BIN1水平与TIMI评分组有正相关性（r=0.186，P=0.003）。结论 BIN1与急性心肌梗死有关。BIN1可能有助于预测急性心肌梗死患者的短期预后，并与NLR具有联合诊断价值。

关键词: 急性心肌梗死, 桥接整合器 1, Killip分级, TIMI评分, 中性粒细胞与淋巴细胞比值

Abstract:

Objective To investigate the correlation of serum levels of bridging integrating factor 1 (BIN1) with acute myocardial infarction (AMI) and Killip class of the patients. Methods We retrospectively collected the data from 94 patients with AMI and 30 healthy individuals for analysis of the correlations of serum BIN1 levels with Killip class, TIMI scores, and neutrophil-to-lymphocyte ratio (NLR). We also assessed the diagnostic value of BIN1 combined with NLR for AMI. Results Serum BIN1 levels were significantly lower in AMI patients than in the healthy individuals (P=0.032). The AMI patients with Killip class I had significantly lower serum BIN1 levels than the healthy individuals (P=0.008). Serum BIN1 level was an independent predictor of AMI with a predictive value of 0.630 (95% CI: 0.513-0.748) at the optimal cutoff level of 0.341 ng/mL, a specificity of 50%, and a sensitivity of 78.5%. Serum BIN1 level was also an independent predictor for Killip class I group in the AMI patients with a predictive value of 0.672 (95% CI: 0.548-0.797) at the optimal cutoff level of 0.287 ng/mL, a specificity of 74.1%, and a sensitivity of 60%. For AMI diagnosis, the combination of NLR and serum BIN1 level had a predictive value of 0.811 (95% CI: 0.727-0.895) at the optimal cutoff level of 0.548 ng/mL, with a specificity of 92.6% and a sensitivity of 62.2%. There was a positive correlation between serum BIN1 level and TIMI score in AMI patients (r=0.186, P=0.003). Conclusion BIN1 is correlated with AMI and can be helpful for predicting short-term prognosis of the patients, and BIN1 combined with NLR has a high diagnostic value for AMI.

Key words: acute myocardial infraction, bridging integrator 1, Killip classifications, TIMI scores, neutrophils-to-lymphocyte ratio

王燕妮, 黄霞, 陈福恒, 高圆圆, 崔向荣, 严琴, 井宣. 急性心肌梗死患者血清中 BIN1 水平与 Killip 分级之间的关系[J]. 南方医科大学学报, 2024, 44(12): 2388-2395.

Yanni WANG, Xia HUANG, Fuheng CHEN, Yuanyuan GAO, Xiangrong CUI, Qin YAN, Xuan JING. Association between serum BIN1 level and Killip class in patients with acute myocardial infraction[J]. Journal of Southern Medical University, 2024, 44(12): 2388-2395.

图/表 9

参考文献 32

1	North BJ, Sinclair DA. The intersection between aging and cardiovascular disease[J]. Circ Res, 2012, 110(8): 1097-108.
2	Abd El Aziz MT, Abd El Nabi EA, El Hamid MA, et al. Endothelial progenitor cells regenerate infracted myocardium with neovascularisation development[J]. J Adv Res, 2015, 6(2): 133-44.
3	Zhang Y, Jiao L, Sun L, et al. LncRNA ZFAS1 as a SERCA2a Inhibitor to Cause Intracellular Ca(2+) Overload and Contractile Dysfunction in a Mouse Model of Myocardial Infarction[J]. Circ Res, 2018, 122(10): 1354-68.
4	Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res, 2021, 128(11): 1728-46.
5	Lin JW, Wang XJ, Zhai SY, et al. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1[J]. J Hematol Oncol, 2022, 15(1): 128.
6	Sudwarts A, Ramesha S, Gao TW, et al. BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia[J]. Mol Neurodegener, 2022, 17(1): 33.
7	Lionello VM, Kretz C, Edelweiss E, et al. BIN1 modulation in vivo rescues dynamin-related myopathy[J]. Proc Natl Acad Sci USA, 2022, 119(9): e2109576119.
8	Zhou K, Hong TT. Cardiac BIN1 (cBIN1) is a regulator of cardiac contractile function and an emerging biomarker of heart muscle health[J]. Sci China Life Sci, 2017, 60(3): 257-63.
9	Li J, Richmond B, Hong TT. Cardiac T-tubule cBIN1-microdomain, a diagnostic marker and therapeutic target of heart failure[J]. Int J Mol Sci, 2021, 22(5): 2299.
10	Mackrill JJ. Evolution of the cardiac dyad[J]. Philos Trans R Soc Lond B Biol Sci, 2022, 377(1864): 20210329.
11	Díaz-Vesga MC, Flores-Vergara R, Riquelme JA, et al. Polycystin-1 is a crucial regulator of BIN1 expression and T-tubule remodeling associated with the development of dilated cardiomyopathy[J]. Int J Mol Sci, 2022, 24(1): 667.
12	Guo J, Tian QH, Barth M, et al. Human BIN1 isoforms grow, maintain, and regenerate excitation-contraction couplons in adult rat and human stem cell-derived cardiomyocytes[J]. Cardiovasc Res, 2022, 118(6): 1479-91.
13	Hong TT, Cogswell R, James CA, et al. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy[J]. Heart Rhythm, 2012, 9(6): 961-7.
14	Kikuchi M, Tahara Y, Yamaguchi J, et al. Executive summary-acute coronary syndrome in the Japan resuscitation council guidelines for resuscitation 2020[J]. Circ J, 2023, 87(6): 866-78.
15	Zhao LY, Sun YX, Li Y, et al. Chinese expert consensus on blood pressure management after percutaneous coronary intervention. Chin J Hypertens, 2022, 30(6): 506-13.
16	Lavie CJ, Gersh BJ. Acute myocardial infarction: initial manifestations, management, and prognosis[J]. Mayo Clin Proc, 1990, 65(4): 531-48.
17	Djuricic I, Calder PC. Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021[J]. Nutrients, 2021, 13(7): 2421.
18	Kalayinia S, Arjmand F, Maleki M, et al. MicroRNAs: roles in cardiovascular development and disease[J]. Cardiovasc Pathol, 2021, 50: 107296.
19	Gambardella J, Wang XJ, Ferrara J, et al. Cardiac BIN1 replacement therapy ameliorates inotropy and lusitropy in heart failure by regulating calcium handling[J]. JACC Basic Transl Sci, 2020, 5(6): 579-81.
20	Dibb KM, Louch WE, Trafford AW. Cardiac transverse tubules in physiology and heart failure[J]. Annu Rev Physiol, 2022, 84: 229-55.
21	Nozaki T, Sugiyama S, Sugamura K, et al. Prognostic value of endothelial microparticles in patients with heart failure[J]. Eur J Heart Fail, 2010, 12(11): 1223-8.
22	Shantsila E, Kamphuisen PW, Lip GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis[J]. J Thromb Haemost, 2010, 8(11): 2358-68.
23	Jiang XX, Zhu YR, Liu HM, et al. Effect of BIN1 on cardiac dysfunction and malignant arrhythmias[J]. Acta Physiol, 2020, 228(3): e13429.
24	Vicent L, Velásquez-Rodríguez J, Valero-Masa MJ, et al. Predictors of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion[J]. Int J Cardiol, 2017, 248: 46-50.
25	Milwidsky A, Greidinger D, Frydman S, et al. Echocardiographic killip classification[J]. J Am Soc Echocardiogr, 2022, 35(3): 287-94.
26	Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond[J]. Am J Physiol Endocrinol Metab, 2009, 296(1): E22-E36.
27	Laury-Kleintop LD, Mulgrew JR, Heletz I, et al. Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy[J]. J Cell Biochem, 2015, 116(11): 2541-51.
28	Hong TT, Yang HH, Zhang SS, et al. Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia[J]. Nat Med, 2014, 20(6): 624-32.
29	Garibaldi M, Böhm J, Fattori F, et al. Novel dominant mutation in BIN1 gene causing mild centronuclear myopathy revealed by myalgias and CK elevation[J]. J Neuromuscul Dis, 2016, 3(1): 111-4.
30	Zhang XW, Xiong H, Duan JL, et al. The prognostic significance of the BIN1 and CCND2 gene in adult patients with acute myeloid leukemia[J]. Indian J Hematol Blood Transfus, 2022, 38(3): 481-91.
31	Ye XM, Zhang P, Zhang YT, et al. GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis[J]. Front Immunol, 2022, 13: 893914.
32	Kala P. Thrombolysis in ST-elevation myocardial infarction is not dead[J]. EuroIntervention, 2021, 16(14): 1129-30.

Variable	Control (n=30)	AMI (n=94)	P
Age (year)	60.32±9.83	61.36±10.44	0.110
Male [n (%)]	13 (43.3)	71 (75.6)	<0.001
ESR (mm/h)	9.47±7.15	10 (12)	0.238
Creatine kinase-MB (ng/mL)	1.2 (0)	1.4 (28.6)	0.665
C-reactive protein (mg/L)	0 (0)	7.5 (18.8)	0.412
Hemoglobin (g/L)	147.19±14.98	143.57±18.76	0.156
Platelet distribution width (fl)	11.4 (1.8)	12.9 (5)	0.010
Neutrophil lymphocyte ratio (%)	1.95±0.72	3.6 (3.4)	<0.001
Glycosylated hemoglobin (%)	5.65±0.38	6.7 (2.7)	0.038
Glucose (mmol/L)	5.1 (0.5)	5.8 (2.8)	0.036
Total cholesterol (mmol/L)	4.83±1.04	4.39±1.08	0.086
Triglyceride (mmol/L)	1.3 (0.9)	1.4 (1.1)	0.214
High-density lipoprotein (mg/dL)	1.31±0.29	1 (0.3)	<0.001
Low-density lipoprotein (mg/dL)	3.02±0.75	2.7 (1)	0.227
Free triiodothyronine (pg/mL)	0 (0)	3.22±0.77	0.092
Thyroid stimulating hormone (uIU/mL)	0 (0)	1.9 (2.2)	0.132
Serum BIN1 (ng/mL)	1 (1.5)	0.7 (0.7)	0.032

Variable	Control (n=30)	AMI (n=94)	P
Age (year)	60.32±9.83	61.36±10.44	0.110
Male [n (%)]	13 (43.3)	71 (75.6)	<0.001
ESR (mm/h)	9.47±7.15	10 (12)	0.238
Creatine kinase-MB (ng/mL)	1.2 (0)	1.4 (28.6)	0.665
C-reactive protein (mg/L)	0 (0)	7.5 (18.8)	0.412
Hemoglobin (g/L)	147.19±14.98	143.57±18.76	0.156
Platelet distribution width (fl)	11.4 (1.8)	12.9 (5)	0.010
Neutrophil lymphocyte ratio (%)	1.95±0.72	3.6 (3.4)	<0.001
Glycosylated hemoglobin (%)	5.65±0.38	6.7 (2.7)	0.038
Glucose (mmol/L)	5.1 (0.5)	5.8 (2.8)	0.036
Total cholesterol (mmol/L)	4.83±1.04	4.39±1.08	0.086
Triglyceride (mmol/L)	1.3 (0.9)	1.4 (1.1)	0.214
High-density lipoprotein (mg/dL)	1.31±0.29	1 (0.3)	<0.001
Low-density lipoprotein (mg/dL)	3.02±0.75	2.7 (1)	0.227
Free triiodothyronine (pg/mL)	0 (0)	3.22±0.77	0.092
Thyroid stimulating hormone (uIU/mL)	0 (0)	1.9 (2.2)	0.132
Serum BIN1 (ng/mL)	1 (1.5)	0.7 (0.7)	0.032

Variable	Univariate analysis		Multivariate analysis
Variable	OR (95% CI)	P	OR (95% CI)	P
Age (year)	5.429 (2.904-10.151)	0.263	-	-
Male [n (%)]	0.248 (0.105-0.586)	0.002	0.337 (0.122-0.932)	0.036
ESR (mm/h)	3.556 (0.359-35.197)	0.278	-	-
CK-MB (ng/mL)	3.909 (1.574-9.703)	0.102	-	-
CRP (mg/L)	6.947 (2.355-10.489)	<0.001	-	0.106
HB (g/L)	1.504 (1.224-1.848)	<0.001	0.51 (0.157-1.660)	0.264
PDW (fl)	1.598 (1.318-1.937)	<0.001	4.88 (1.506-15.812)	0.008
NLR (%)	1.731 (1.403-2.136)	<0.001	3.119 (1.162-8.368)	0.024
HbA1c (%)	2.532 (1.716-3.738)	<0.001	8.628(1.899-39.198)	0.005
Glucose (mmol/L)	1.681 (1.381-2.048)	<0.001	-	0.269
TC (mmol/L)	1.604 (1.311-1.962)	<0.001	0.302 (0.101-0.908)	0.033
Triglyceride (mmol/L)	1.632 (1.365-1.950)	<0.001	1.311 (0.523-3.285)	0.564
HDL (mg/dL)	1.694 (1.354-2.119)	<0.001	0.347 (0.021-5.857)	0.463
LDL (mg/dL)	1.641 (1.337-2.041)	<0.001	0.536 (0.206-1.392)	0.200
FT3 (pg/mL)	4.916 (2.152-11.230)	<0.001	0.254 (0.015-4.267)	0.341
TSH (uIU/mL)	4.753 (2.072-10.904)	<0.001	2.401 (0.271-21.301)	0.432
Serum BIN1 (ng/mL)	1.825 (1.418-2.350)	<0.001	0.389 (0.161-0.942)	0.031

Variable	Univariate analysis		Multivariate analysis
Variable	OR (95% CI)	P	OR (95% CI)	P
Age (year)	5.429 (2.904-10.151)	0.263	-	-
Male [n (%)]	0.248 (0.105-0.586)	0.002	0.337 (0.122-0.932)	0.036
ESR (mm/h)	3.556 (0.359-35.197)	0.278	-	-
CK-MB (ng/mL)	3.909 (1.574-9.703)	0.102	-	-
CRP (mg/L)	6.947 (2.355-10.489)	<0.001	-	0.106
HB (g/L)	1.504 (1.224-1.848)	<0.001	0.51 (0.157-1.660)	0.264
PDW (fl)	1.598 (1.318-1.937)	<0.001	4.88 (1.506-15.812)	0.008
NLR (%)	1.731 (1.403-2.136)	<0.001	3.119 (1.162-8.368)	0.024
HbA1c (%)	2.532 (1.716-3.738)	<0.001	8.628(1.899-39.198)	0.005
Glucose (mmol/L)	1.681 (1.381-2.048)	<0.001	-	0.269
TC (mmol/L)	1.604 (1.311-1.962)	<0.001	0.302 (0.101-0.908)	0.033
Triglyceride (mmol/L)	1.632 (1.365-1.950)	<0.001	1.311 (0.523-3.285)	0.564
HDL (mg/dL)	1.694 (1.354-2.119)	<0.001	0.347 (0.021-5.857)	0.463
LDL (mg/dL)	1.641 (1.337-2.041)	<0.001	0.536 (0.206-1.392)	0.200
FT3 (pg/mL)	4.916 (2.152-11.230)	<0.001	0.254 (0.015-4.267)	0.341
TSH (uIU/mL)	4.753 (2.072-10.904)	<0.001	2.401 (0.271-21.301)	0.432
Serum BIN1 (ng/mL)	1.825 (1.418-2.350)	<0.001	0.389 (0.161-0.942)	0.031

Variable Control (n=30)		Killip Ⅰ (n=58)	Killip Ⅱ (n=13)	Killip Ⅲ (n=5)	Killip Ⅳ (n=12)	P
Age (year)	43.63±9.83	60.21±10.42	61.15±9.90	61.00±11.47	70.33±6.71	0.001*
Male [n (%)]	16.3 (13)	56.3 (45)	11.3 (9)	5 (4)	11.3 (9)	0.022*
ESR (mm/h)	9.47±7.15	10.10±5.03	26.00±19.52	4 (0)	17.17±12.84	0.169
BNP (pg/mL)	-	75.7 (139.1)	68.4 (158.7)	437.57±558.40	792.82±649.66	0.012*
cTnI (ng/mL)	-	4111.9 (25542.3)	13379.2 (22279.2)	13125.2 (0)	1483 (19718.4)	0.559
FT3 (pmol/L)	0 (0)	3.28±0.79	3.46±0.29	3.00±0.67	2.8 (1.3)	0.141
TSH (mol/L)	0 (0)	2.09±1.45	2.82±1.39	0.6 (0)	1.81±1.41	0.192
D-Dimer (ng/mL)		101 (194.5)	230.75±181.98	148.80±113.60	169.5 (428.7)	0.892
CKMB (ng/mL)	10.2 (0)	2.5 (29.5)	1.1 (47)	1 (0)	10.7 (0)	0.971
hs-CRP (mg/L)	0 (0)	2.6 (3.8)	10.3 (6.7)	2.42±2.10	9.55±1.42	0.040*
TnI (ng/mL)	-	1.1 (4.9)	1 (8)	0.1 (5877.1)	15.97±15.60	0.388
CRP (mg/L)	0 (0)	12.4 (16.3)	79.86±87.14	20.5 (0)	2.8 (12)	0.503
HB (g/L)	147.19±14.98	142.95±18.00	136.15±24.10	146.3±12.8	140.64±12.96	0.582
PDW (fl)	11.4 (1.8)	12.4 (4.6)	13.57±3.89	14.6±3.04	15.9 (5.9)	0.017*
NLR (%)	2.8 (2.9)	3 (2.6)	3.98 (3.53)	5.32±2.55	7.97±4.10	0.001*
HbA1c (%)	5.65±0.38	6.7 (2.2)	7.33±1.57	6.43±1.23	6.2 (2.5)	0.247
Glucose (mmol/L)	5.1 (0.5)	5.4 (2.5)	7 (7.04)	4.8 (2.9)	5.9 (3.6)	0.024*
TC (mmol/L)	4.83±1.04	4.29±1.10	4.52±1.19	4.48±1.44	4.3 (1.5)	0.403
Triglyceride (mmol/L)	1.3 (0.9)	1.4(1)	1.60±0.64	2.34±2.06	1.60±0.84	0.757
HDL (mg/dL)	1.31±0.29	1 (0.4)	1.1 (0.6)	1.41±0.61	1.1 (0.8)	0.019*
LDL (mg/dL)	3.02±0.75	2.74±0.87	2.7 (1.6)	3.1 (1.1)	2.7 (1)	0.658
CK (ng/mL)	76 (0)	327.60 (1712.2)	3437.18±3034.36	1574.00±2290.10	94.5 (1288.83)	0.192
Serum BIN1 (ng/mL)	1 (1.5)	0.63 (0.5)^a	0.68 (0.55)	2.2 (6)^b	1.5 (12.1)^c	0.008*

急性心肌梗死患者血清中 BIN1 水平与 Killip 分级之间的关系

Association between serum BIN1 level and Killip class in patients with acute myocardial infraction

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

Factor	Killip Ⅰ	Killip Ⅱ	Killip Ⅲ	Killip Ⅳ
CRP (mg/mL)	12.39 (3.19-3.23)^a	77.85 (0-218.51)	20.47 (0-276.25)	2.84 (0-20.08)
ESR (mm/h)	10 (6.71-13.71)	25 (22.49-74.49)	4 (0-29.41))	17 (3.69-30.65)
hsCRP (mg/mL)	2.55 (1.91-5.45)	10.30 (2.70-12.60	2.06 (0-7.64)	10 (7.29-11.80)^b
NLR (%)	2.99 (2.91-4.56)	3.98 (2.38-8.56)	5.58 (1.26-9.37)	6.68 (5.21-10.73)^b

Variable	Control (n=30)	TIMI Scores			P
Variable	Control (n=30)	0-3 (n=42)	4-6 (n=45)	7-14 (n=6)	P
Age (year)	43.63±9.83	57.93±10.42	63.22±9.59	72.5±6.35	0.029^abcd
SBP (mmHg)	110 (20)	127 (21.5)	121.5 (29.5)	102.83±18.55	0.384
BNP (pg/mL)	-	71.3 (103.1)	105 (252.5)	518.92±513.68	0.159
D-Dimer (mg/L)	-	88.5 (125.3)	131 (280)	296.5 (1325.5)	0.358
hs-CRP (mg/L)	0 (0)	588.5 (17695.3)	5164.5 (25057.6)	0 (0)	0.158
PDW (fl)	11.4 (1.8)	12.9 (4.4)	12.4 (5.3)	13.68±2.72	0.97
NLR (%)	2.8 (2.9)	2.6 (2.8)	3.74 (3.73)	7.97±4.02	0.04^abe
HbA1c (%)	5.65±0.38	5.6 (1.7)	7.64±1.85	6.1 (0.9)	0.035
Glucose (mmol/L)	5.1(0.5)	5.3 (1.8)	6.3 (5.4)	6.30±1.42	0.009^bd
Breath (rate)	19 (0.6)	20 (1)	20 (0.3)	20 (1.3)	0.857
FT3 (pg/mL)	0 (0)	3.26±0.64	3.34±0.72	2.51±1.21	0.822
Pluse	75 (18.69)	72 (18)	76.05±15.49	77.83±25.22	0.97
Heart (rate)	75 (17)	72 (19)	76.52±16.22	77.83±25.21	0.78
TSH (uIU/mL)	0 (0)	2.92±1.29	1.38 (1.32)	2.30±1.43	0.807
LDL (mg/dL)	3.02±0.75	2.74±0.86	2.8 (1.1)	2.6 (0.5)	0.43
TC (mmol/L)	4.83±1.04	4.37±1.11	4.41±1.09	3.9 (0.8)	0.707
HDL (mg/dL)	1.31±0.29	1 (0.3)	1 (0.2)	0.92±0.15	0.181
LV (%)	-	35.23±7.66	32.49±8.32	39.6 (0)	0.248
EF (%)	-	63.58±10.93	57.49±13.55	69.6 (0)	0.118
LVID (cm)	-	4.25 (3.17)	4.6 (0.9)	4.7 (0)	0.22
LVPDW (cm)	-	0.9 (0.2)	1 (0.2)	0.9 (0)	0.306

[1]	邓钰莹, 陈华锋, 李功辉, 陈立桁, 傅强. 慢性肾脏病对肌钙蛋白诊断急性心肌梗死准确性的影响[J]. 南方医科大学学报, 2023, 43(2): 300-307.
[2]	唐娟, 陈娟, 林国新, 张浩, 桂明, 李楠楠, 谷依红, 罗林娟, 孙剑. 中性粒细胞/淋巴细胞、血小板/淋巴细胞比值是评价托法替尼治疗后类风湿关节炎活动性的有效指标[J]. 南方医科大学学报, 2023, 43(10): 1651-1656.
[3]	侯季秋，陈雅丽，马迪，王超，靳会会，安莹，赵海滨. 从CXCL12/CXCR4轴探析空瓶诱导的慢性情绪应激对急性心肌梗死大鼠炎性因子的影响[J]. 南方医科大学学报, 2020, 40(05): 624-631.
[4]	朱建，杨燕，胡司淦，李辉，张恒. Connexin 43在急性冠脉综合征患者外周血单核细胞中的表达[J]. 南方医科大学学报, 2019, 39(04): 471-.
[5]	李慧娣，向定成，张金霞，段天兵，龙锋，李爱敏. 急性心肌梗死早期脑钠肽浓度的动态演变规律及其对心力衰竭的诊断价值[J]. 南方医科大学学报, 2018, 38(01): 112-.
[6]	姜大庆，谷天祥，徐兆发，刘爽，李学渊. 心肌球源性心肌干细胞联合心室肌细胞外基质治疗大鼠急性心肌梗死效果[J]. 南方医科大学学报, 2016, 36(10): 1316-.
[7]	叶刚，刘丽，余健，甘峰，韦宏成. 血清铁降低对急性ST段抬高心肌梗死患者院内泵功能衰竭的预测价值[J]. 南方医科大学学报, 2015, 35(04): 610-.
[8]	申健，张旭，李志明，谢桂庭，农盛雄，申源生. 急性ST段抬高型心肌梗死患者外周血apelin的水平变化及意义[J]. 南方医科大学学报, 2015, 35(03): 407-.
[9]	王亚蓉，郭壮波，黄丽萍. 三种心肌损伤标志物对早期急性心肌梗死的诊断价值[J]. 南方医科大学学报, 2014, 34(09): 1347-.
[10]	尹巧香，赵玉生，王姮，裴志勇. 延迟增强核磁共振评估经皮球囊封堵冠状动脉法制备的小型猪心肌梗死模型[J]. 南方医科大学学报, 2013, 33(01): 34-.
[11]	赵映，陈韵岱，田峰，王长华，胡舜英，王晶，杨俊杰. 急性心肌梗死患者急诊PCI术后无复流的危险因素分析[J]. 南方医科大学学报, 2012, 32(02): 261-.
[12]	宋元彬，丘若峰，邝健，黄裕立，蔡安平，戴刚，麦炜颐. 阿托伐他汀对大鼠急性心肌梗死后心功能及TGF-β1信号通路的影响[J]. 南方医科大学学报, 2012, 32(02): 202-.
[13]	林泽鹏，舒平春，廖志坚，王小庆，刘强. 瑞舒伐他汀对急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后存活心肌功能及动脉粥样硬化的影响[J]. 南方医科大学学报, 2011, 31(10): 1789-.
[14]	黄炫生张励庭袁勇董剑廷刘卫其韩莹邓志华. 急性心肌梗死急诊介入治疗疗效与血管再通时间的关系[J]. 南方医科大学学报, 2007, 27(01): 119-.
[15]	肖长华；杨希立；谭海斌；陈军；许兆延；张健愉；. 急性心肌梗死早期冠状动脉介入治疗后血浆脑钠素水平与肌酸磷酸激酶MB峰值变化的关系[J]. 南方医科大学学报, 2006, 26(11): 1665-1666.